J Med Chem

ISSN 0022-2623; 1520-4804;

2 papers in the library · 5 citations · publishing 2020-2025

Papers

Targeting the 5-HT2A Receptor for Developing Psychedelic Drugs and Beyond.

J Med Chem May 1, 2025 Saghir Ali, Xiaochen Tian, Kathryn A. Cunningham et al. 5 citations

The 5-HT2A receptor is a key target for psychedelic drugs, and research is exploring its role in developing new treatments for psychiatric disorders. This review examines the receptor's structure, function, and signaling pathways, highlighting how psychedelics like psilocybin and LSD interact with it to produce their effects. The authors discuss potential therapeutic applications beyond psychedelic experiences, including for depression, anxiety, and addiction, while also considering the challenges of designing drugs that retain therapeutic benefits without hallucinogenic side effects. The work synthesizes current knowledge on 5-HT2A receptor pharmacology and its implications for drug development.

DOI: 10.1021/acs.jmedchem.5c01156 Full text

Identification of Psychoplastogenic N,N-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure-Activity Relationship Studies.

J Med Chem January 24, 2020

A series of N,N-dimethylaminoisotryptamine (isoDMT) analogues were synthesized and tested to identify which structural features promote psychoplastogenic activity—the ability to promote neural plasticity. Through structure-activity relationship studies, several analogues were found to induce neurite growth in cortical neurons, with some showing potency comparable to or greater than known psychoplastogens. The findings suggest that specific modifications to the isoDMT scaffold can enhance neuroplasticity-promoting effects, providing a basis for developing novel compounds that may have therapeutic potential for neuropsychiatric disorders.

DOI: 10.1021/acs.jmedchem.9b01404 Full text